Igor I. Slukvin, MD, PHD
Professor, Pathology & Laboratory Medicine
- Organ System/Disease Focus:
- Blood development/disease
- Aligned Research Focus:
- Hematopoietic and endothelial development from human pluripotent stem cells, hematopoietic stem cell (HSC) biology
- Researchers discover effective way to generate powerful blood cells for immunotherapy, 25 May 2018
- Igor Slukvin’s Research Featured in Cell Reports, 12 July 2017
- Researchers forge primitive human leukemia cells in lab, 1 December 2015
- Wisconsin scientists find genetic recipe to turn stem cells to blood: 14 July 2014
- New induced stem cells may unmask cancer at earliest stage; 4 February 2011
- Additional appointments: Cell & Regenerative Biology (joint appointment); Wisconsin National Primate Center (affiliate scientist)
- Slukvin Laboratory Home Page
Pluripotent stem (PS) cells, including embryonic stem (ES) and induced pluripotent stem (iPS) cells, represent a unique population of cells capable of self-renewal and differentiation. Pluripotent stem cells can form any cell type in the body and serve as a scalable cell source for transplantation and tissue engineering. The main focus of my research is to establish the differentiation of human pluripotent stem cells into hematopoietic progenitors and mature blood cells in order to understand molecular mechanisms of early hematopoietic differentiation and provide a novel source of cells for bone marrow transplantation, transfusion and cancer immunotherapy. Recently we developed methods for efficient differentiation of PS cells into myelomonocytic and erythroid cells and identified the hierarchy of mesodermal and hematoendothelial progenitors leading to the formation of blood cells and hematopoiesis-supportive elements. In addition, we developed technologies for efficient reprogramming of normal and neoplastic blood cells into iPS cells. Currently my laboratory is working on 1) identification of genes essential for acquisition of long-term engraftment potential by pluripotent stem cell-derived hematopoietic cells; 2) establishing non-human primate models of ES cell and iPS cell-based cellular therapy for blood and immune system disorders; 3) developing iPS cell based models for blood cancer stem cell development.
- Mesquitta WT, Wandsnider M, Kang H, Thomson J, Moskvin O, Suknuntha K, Slukvin II. UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells. Sci Rep. 2019 Apr 29;9(1):6622.
- Kumar A, Lee JH, Suknuntha K, D’Souza SS, Thakur AS, Slukvin II. NOTCH Activation at the Hematovascular Mesoderm Stage Facilitates Efficient Generation of T Cells with High Proliferation Potential from Human Pluripotent Stem Cells. J Immunol. 2019 Feb 1;202(3):770-776.
- Kang HJ, Mesquitta WT, Jung HS, Moskvin OV, Thomson JA and Slukvin II. GATA2 is Dispensable for Specification of Hemogenic Endothelium but Promotes Endothelial-to-Hematopoietic Transition. Stem Cell Reports 2018 Jul 10;11(1):197-211.
- Uenishi G, Jung HS, Kumar A, Park MA, Hadland BK, McLeod E, Raymond M, Moskvin O, Zimmerman CE, Theisen DJ, Swanson S, Tamplin O, Zon LI, Thomson JA, Bernstein ID and Slukvin II. NOTCH Signaling Specifies Arterial-Type Definitive Hemogenic Endothelium from Human Pluripotent Stem Cells. Nature Communications 2018 May 8;9(1):1828.
- Park MA, Kumar A, Jung HS, Uenishi G, Moskvin OV, Thomson JA, and Slukvin II. Activation of Arterial Program Drives Development of Definitive Hemogenic Endothelium with Lymphoid Potential. Cell Reports 2018 May 22, 23: 2467–2481